CellCentric
United Kingdom, Cambridge
About CellCentric
CellCentric is a British biotech developing an oral p300/CBP inhibitor for heavily pretreated multiple myeloma patients, currently in Phase 2a trials.
Latest Funding
Series C+Announced 2026-05-06
Buying Signals
Where the capital is going, and whether it's already started moving.
Spend Intent
5 signals · where the capital is going
Funding positions CellCentric for a potential IPO following pivotal trial readouts
fiercebiotech.com
Advance inobrodib through pivotal clinical development toward registration as a first-in-class oral p300/CBP inhibitor
cityam.com
+3 more capital deployment signals · confidence ratings · source articles
Sign up freeIn the news
Selling to CellCentric? You're in the right place.
Knowing they raised is the start. The edge is what's attached to CellCentric.
Spend intent
Where this round will be spent.
Hiring signals
Which departments are growing.
Verified contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Ask AI
What is the unique value proposition of CellCentric, and who are their main competitors?
Sign up free to ask AI about CellCentric
Our AI has read their website, news, and funding history. 25 credits included with every free account.
Sign up free: 25 credits includedAuto-matched to your ICP
Every company, scored against your profile. Automatically.
Industry
High
Size
Mid
Stage
High
Match score blends industry, company size, growth stage, tech stack, and geography. The moment you set your ICP, every company in our database gets scored.
Investors
Venrock Healthcare Capital Partners
Lead investor · Series C+
2 funding rounds total
Funding History
Full accessTech Stack
CookieYes
HTTP/3
WordPress
Key Highlights
AI InsightsFunding will support Phase 2/3 studies and potential accelerated FDA approval for their multiple myeloma candidate.
AI reads their website, press releases, and funding context to surface what makes them unique - so you tailor your pitch before the first call.
Try it free →Generates a personalized cold email based on their funding round, capital deployment signals, and company context. Ready to send in under 10 seconds.
Try it free →Short, personalized connection request crafted around their recent funding and what your product can help them achieve with it.
Try it free →Maps their competitive landscape with AI - invaluable context before your first call and for positioning your pitch against their alternatives.
Try it free →Extracts capital deployment signals from their funding news - reach out knowing exactly where they're investing and why your product fits.
Try it free →Similar Companies
Discover companies similar to CellCentric
Selling to CellCentric? You're in the right place.
Knowing they raised is the start. Our difference is what comes attached to CellCentric.
Spend Intent
Where this round will be spent.
Hiring Signals
Which departments are growing.
Verified Contacts
Who actually decides.
No credit card. Five minutes, no approvals.
Free weekly newsletter on startup funding.
20 rounds, ranked by amount. Industry and stage breakdowns. A short market note. One email, free, no noise. 2,000+ subscribers.
No spam, ever. Unsubscribe with one click.